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Background: Relapse occurs in 50% of pediatric ependymoma cases and has poor prognosis. Few
studies have investigated the clinical progress of relapseddisease, and treatment lacks a standard-
ized approach.
Methods andmaterials:Weanalyzed302pediatric ependymoma cases. Tumor, demographic, and
treatment variables were investigated for association with relapse risk, time to recurrence, and
survival after relapse. DNAmethylation profilingwas performed for 135/302 cases, and predomi-
nant subgroupswereEPN_PFA (n=95) andEPN_RELA (n=24). Chromosome1q statuswas ascer-
tained for 185/302 cases by fluorescent in-situ hybridization (FISH),multiplex ligation-dependent
probe amplification (MLPA), and DNAmethylation profiles.
Results: Sixty-two percent of cases relapsed, with amedian of two recurrenceswith no difference
betweenposterior fossa and supratentorial locations (66%vs55%relapse rate).Onehundred sev-
enteen (38%) cases relapsed within two years and five (2%) beyond 10 years. The late relapses
were clinically heterogeneous. Tumor grade and treatment affected risk and time to relapse vari-
ably across subgroups. After relapse, surgery and irradiation delayed disease progression with a
minimal impact on survival across the entire cohort. In the EPN_PFA and EPN_RELA groups, 1q
gain was independently associated with relapse risk (subhazard ratio [SHR] 4.307, P = 0.027 and
SHR 1.982, P = 0.010, respectively) while EPN_PFA had increased relapse risk compared with
EPN_RELA (SHR= 0.394, P= 0.018).
Abbreviations: CCLG, Children’ Cancer and Leukaemia Group; CNS, central nervous system; CSI, craniospinal irradiation; DNA, deoxyribonucleic acid; DNET, dysembryonic neuroepithelial
tumor; EFS, event-free survival; EPN, ependymoma; FFPE, formalin-fixed, paraffin-embedded; FISH, fluorescent in-situ hybridization; GTR, gross total resection;MLPA, multiplex
ligation-dependent probe amplification; OS, overall survival; PF, posterior fossa; PFA, posterior fossa A; PFB, posterior fossa B; RELA, V-rel avian reticuloendotheliosis viral oncogene homolog A;
SHR, subhazard ratio; SIOP, International Society of Paediatric Oncology; ST, supratentorial; STR, subtotal resection;WHO,World Health Organization; YAP, yes-associated protein.
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Conclusions: Recurrent pediatric ependymoma is an aggressive disease with poor outcomes, for
which current treatments are inadequate. We report that chromosome 1q gain increases relapse
risk in commonmolecular subgroups in childrenbut adeeperunderstandingof theunderlyingbiol-
ogy at relapse and novel therapeutic approaches are urgently needed.
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1 INTRODUCTION
Ependymoma is the second commonest malignant pediatric brain
tumor and is associated with poor outcomes.1 Relapse occurs in 50%,
with a five-year overall survival rate of approximately 25%.2
Therapy consists of surgery followed by radiotherapy, with
chemotherapy for young children and those with a subtotal resection
(STR).3 Gross total resection (GTR) and irradiation have been asso-
ciated with better outcomes,4-12 but the benefits of chemotherapy
are less clear.3,6,12-17 The strongest reported risk factor for relapse is
STR.10,18,19
Therapeutic approaches at relapse lack a standardized approach,20
but further surgery and reirradiation have been proposed to improve
prognosis.2,21 Studies suggest that reirradiation of recurrent ependy-
moma is safe and feasible.21-23 However, there are risks of brainstem
radio-necrosis and late effects. Evidence that chemotherapy is bene-
ficial at recurrence is limited to a few small studies.24-26 Novel thera-
pies have been investigated at relapse but have been largely limited to
phase 1 studies.27-29 Despite the lack of treatment consensus, there
are no current multicenter randomized trials for recurrent ependy-
moma.
Molecular classification of ependymoma has advanced, with RELA-
fusion positive (EPN_RELA) supratentorial (ST) ependymoma intro-
duced to the WHO classification of CNS tumors.30 Studies describe
nine molecular ependymoma subgroups based on DNA methylation
and gene expression.31-33 These subgroups are now being integrated
with knownmolecular characteristics to enhance disease understand-
ing, in particular, associations have been identified between chro-
mosome 1q gain and the aggressive posterior fossa A (EPN_PFA)
tumor.12,31
Well-annotated studies of relapsed ependymoma have been small
andoften comprisedofmixedadult andchildhoodcohorts.2,26,34-37 We
assembled a large cohort of 302 children with ependymoma to better
understand recurrence. DNAmethylation profiling enabled us to place
this in the context of molecular subgrouping.31
We highlight that recurrent pediatric ependymoma is aggressive
with poor outcomes for the predominant pediatric subgroups. Current
interventions are associated with reduced relapse risk and increased
disease-free survival time, but do not prevent recurrence. Interven-
tions at relapse haveminimal impact on long-term survival, underscor-
ing an urgency for new therapies.
2 METHODS
2.1 Patient cohort
Three hundred two patients (< 18 years) were included. One hundred
seventy patients were part of two international trials (SIOP 1992,3
199938). Two hundred fifty-four patients were treated in the UK, 16
in the USA, 18 in Holland, 7 in Dublin, 4 in Denmark, 2 in Spain, and
1 in Sweden. Clinical information and tumor specimens were obtained
via the Children’s Cancer and Leukaemia Group. Ethical approval was
obtained from the UK-wide Multicentre Research Ethics Committee
(MREC11/EM/0076). Consent for inclusion in biological studies was
obtained in line with national regulations.
Patients with grade II or III ependymoma diagnosed after 1990
were included.Diagnosiswas confirmedby central pathology review in
Nottingham. Fifteen caseswere centrally reviewed at theUniversity of
Colorado, Denver. Nine cases received only local review. DNA methy-
lation profiling was available for 135 primary cases.
Recurrence was defined as return of a tumor following GTR or clin-
ical or radiological progression following STR. Imaging was centrally
reviewed at primary diagnosis but reviewed locally at relapse.
Treatment was stratified by age at presentation. Children under
three years were treated with surgery followed by chemotherapy, fol-
lowing the SIOP 92 protocol.3 Focal radiotherapy was considered at
recurrence. Children over three years received involved field radio-
therapy within four weeks of surgery if GTR achieved, and involved
field radiotherapy within three weeks of completion of chemotherapy
if STR achieved, following the SIOP 99 study protocol.38 Craniospinal
irradiation (CSI) was not employed routinely at diagnosis. Approaches
at recurrence varied by locality but involved resection followed by
chemotherapy and/or focal radiotherapy or CSI. Proton beam radio-
therapy was not used.
2.2 DNAmethylation profiling
DNA was extracted using the AllPrep DNA/RNA FFPE kit (Qiagen,
Germany) for FFPE tissue or QIAmp DNA mini kit (Qiagen, Germany)
for frozen tissue. Profiling was performed on 1000 ng bisulphite-
converted DNA using Infinium HumanMethylation450 BeadChip
arrays (Illumina, SanDiego, USA) at UCLGenomics (UK). Ependymoma
subgroups were assigned as previously described.31 Copy-number
variation was calculated using the Conumee R package.
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2.3 Statistical analysis
Cases were analyzed as a combined cohort to allow comparison with
previous studies, before subgroup analysis of tumors by intracra-
nial compartment (PF and ST) and major subgroups (EPN_PFA and
EPN_RELA).
Differences in time to relapsewere tested using theWilcoxon rank-
sum test. Overall and event-free survival (OS and EFS) analyses were
performed using a supremum log-rank test. Kaplan-Meier curves and
Cox proportional hazards models were generated using R packages
“Survival” and “Survminer.”39 OSwas defined as the timebetweendate
of diagnosis and death, and EFS as the time between date of diagno-
sis and recurrence or death. Surviving patients were censored at last
follow-up.
Fine and Gray40 competing risks regression was used to test risk
of recurrence using STATA (Statacorp, Texas, USA). Death before first
recurrence was included as a competing risk.
2.4 Chromosome 1q FISH
Gain of chromosome 1q was determined using dual color interphase
FISH as previously described, using commercial 1q25 and 1p36 probes
(AbbotMolecular, Illinois, USA).41
2.5 Multiplex ligation-dependent probe
amplification (MLPA)
1q25.1 copy number was determined using probes for LHX4 (6 exons)
(http://www.mrc-holland.com). MLPA was performed using the Salsa
MLPA kit (MRC-Holland, Amsterdam, Holland).
3 RESULTS
3.1 Group and treatment characteristics
Three hundred two children with ependymoma, diagnosed between
1990 and 2015, were included (Table 1). Median OS was 170 months
(range, 0-260). 114 (38%) patients died, while 184 (62%) were alive at
most recent follow-up (median 97 months, range, 8-260). Median age
at diagnosis was 39 months (range, 0-225).There were 216 (72%) PF,
73 (24%) ST, and 11 (4%) spinal cases (Table 1).
The GTR rate across the whole cohort was 52%. At primary diagno-
sis, in addition to surgery, 117/136 (86%) children under three years,
received chemotherapy alone. Fifteen of 136 (11%) children received
focal radiotherapy with or without chemotherapy. Four of 136 (3%)
children received no treatment after surgery.
One hundred sixteen of 145 (80%) children age over 3 received
either focal radiotherapy (79/116, 68%) or chemotherapy followed
by radiotherapy (37/116, 32%), dependent on the extent of tumor
resection. Twenty-two of 145 (15%) children age over 3 received
chemotherapy only. Seven of 145 (5%) received no treatment after
surgery. In all age groups, the childrenwho received no treatment after
surgery had spinal tumors (n= 4), died following surgery (n= 2), or had
GTRwith decision for no further treatment (n= 5).
At first recurrence, in addition to surgery, 99/144 (69%) patients
with data received radiotherapy of any type. The remainder (45/144,
31%) received chemotherapy. Of those with data on radiotherapy type
at first recurrence, 26/37 (70%) received focal treatment while 11/37
(30%) received CSI.
The majority of patients in the recurrent cohort received their first
radiotherapy at recurrence (70/99, 71%) and a smaller proportion
(25/99, 25%) received reirradiation. Reirradiation statuswas unknown
for 4/99 (4%).
DNA methylation profiles were generated for 135 primary tumors
plus 92 relapses from 67 patients. Clinical associations for pri-
mary tumors agreed with previous reports (Supporting Information
Figure S1).31 The cohort contained predominantly EPN_PFA (n = 95)
and EPN_RELA (n= 24) cases.
Four patients had nonependymoma profiles at recurrence, two
likely due to normal brain contamination. Of the remaining two, one
was classified as spinal subependymoma and the other glioblastoma.
The primary tumor was excluded for both.
3.2 Relapse pattern
Of the combined cohort of 302 patients, 186 (62%) relapsed with a
five-year cumulative incidence of 57%.One hundred forty-three of
216 (66%) PF tumors relapsed compared with 40/73 (55%) ST tumors.
In PF and ST groups, there was over 90% long-term OS for patients
without relapse (Supporting Information Figure S2). The number
of recurrences ranged from one to six (median two) for PF tumors
and one to eight (median one) for ST tumors. For both locations the
risk of further relapse remained approximately 50% each time (Fig-
ure 1A and D). Subsequent relapses occurred more rapidly in the PF
(P< 0.001) (Figure 1B), but not the ST, cohort (P= 0.430) (Figure 1E).
Median time to first relapse for the combined cohortwas18months
(range, 0-165), 19 months for PF tumors (0-165), and 16.5 months
for ST tumors (1-124). Sixty-nine (38%) patients relapsed beyond two
years and five (3%) after 10 years. The patients who relapsed latewere
heterogeneous. Four had PF, and one a ST, tumor. There were two
EPN_PFA, one EPN_PFB and two with unknown subgroups. Three of
five were alive at follow-up. Three received chemotherapy and radio-
therapy and two chemotherapy alone. Three of five achieved GTR.
Only the ST case had 1q gain.
The total number of relapses was associated with OS in the PF
cohort (P = 0.041), survival being better for patients with only one
recurrence (Figure 1C), but not in the ST cohort (Figure 1F).
A higher proportion of EPN_PFA and EPN_YAP cases relapsed
than other subgroups (Figure 2A). However, EPN_RELA patients who
recurred experienced most relapses (mean: EPN_PFA 2, EPN_PFB 1,
EPN_RELA 3, EPN_YAP 1). Relapse rate was low in EPN_PFB and
EPN_SPINE (Figure 2B). Two of nine EPN_PFB cases relapsed but
both were alive 10 years after diagnosis. Four of five EPN_YAP cases
relapsed; twoweredisease free at10years, one relapseda second time
but was alive after five years and one died after threemonths.
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Age at diagnosis (years) 0-5 151 29 0 1
5-10 40 23 4 1
10-15 16 14 6 0
15-18 8 5 1 0
Unknown 1 2 0 0
Gender Male 124 36 7 2
Female 88 37 4 0
Unknown 4 0 0 0
Grade WHO II 131 29 11 2
WHO III 84 44 0 0
Unknown 1 0 0 0
Extent of resection Gross total 101 35 6 2
Subtotal 93 34 4 0
Unknown 22 4 1 0
Focal radiotherapy at primary diagnosis Yes 85 39 7 0
No 123 30 4 1
Unknown 8 4 0 1
Chemotherapy at primary diagnosis Yes 143 41 3 1
No 59 27 8 1
Unknown 14 5 0 0
Treatment timing at primary diagnosis CT
d
only 114 25 0 1
Focal RT
e
only 56 26 4 0
CT followed by focal RT 28 14 3 0
None 4 3 4 0
Unknown 14 5 0 1
Chromosome 1q gain No gain 104 37 3 0
Gain 29 12 0 0
Unknown 83 24 8 2
Molecular subgroup EPN_PFA 92 3 0 0
EPN_PFB 9 0 0 0
EPN_RELA 0 24 0 0
EPN_YAP 0 5 0 0






Methylation patterns were determined for 40 primary tumors and
paired first recurrences. Thirty-nine (98%) remained in the same sub-
group at relapse. One EPN_PFA switched to a DNET, which could have
represented normal brain contamination. All profiled second relapses
(n= 11) remained in the same subgroup.
3.3 Factors associatedwith relapse risk
In multivariate analysis of the combined cohort, factors associated
with increased risk of relapse were younger age, STR, no radiotherapy
at diagnosis, and chromosome 1q gain (Supporting Information Tables
S1 and S2).
In univariate analysis of PF tumors, greater risk of relapsewas asso-
ciated with younger age, no radiotherapy, receipt of chemotherapy,
and chromosome 1q gain, but in multivariate analysis only 1q gain
remained significant (subhazard ratio [SHR] 3.042, P < 0.001). For ST
tumors, STR and 1q gain were associated with relapse risk in univari-
ate and multivariate analyses (SHR0.320,P = 0.004 and SHR2.770,
P= 0.004) (Table 2).
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F IGURE 1 (A) Pattern of relapsed posterior fossa ependymoma. The probability of further relapse remained at approximately 50%. One case
was not includedwhere the total number of relapses was unknown. (B) The interval between each recurrence significantly shortened for each
subsequent recurrence in the PF cohort (P< 0.001). Each survival curve represents the time for each numbered recurrence to occur. (C) Patients
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EPN_PFA cases had a higher risk of relapse than EPN_RELA cases
(SHR= 0.394, P= 0.018). For EPN_PFA tumors only grade (SHR 1.791,
P = 0.027) and 1q gain (SHR 1.982, P = 0.010) were associated with
relapse risk while for EPN_RELA only 1q gain (SHR 4.307, P = 0.027)
was associated (Table 3).
3.4 Factors associatedwith time to first relapse
The 186 relapsed patients were analyzed for factors associated with
time to first relapse (Supporting Information Table S3).
In univariate analysis of the combined cohort, faster relapse was
seen for grade III tumors (16 vs 22 months, P = 0.001), STR (17 vs
20 months, P = 0.018), receipt of chemotherapy (17 vs 24 months,
P = 0.007) and lack of radiotherapy (23 vs 17 months, P = 0.002)
(Supporting Information Figure S3A-C, E). Significantly delayed radio-
therapy (beyond four months after surgery) did not have an impact
(P = 0.173). Combined GTR and radiotherapy delayed relapse com-
pared with no radiotherapy (31 vs 18 months, P = 0.008) (Supporting
Information Figure S3D). In multivariate analysis of the combined
cohort, grade III (HR 1.572, P = 0.030) and STR (HR 0.642, P = 0.048)
remained associatedwith faster relapse (Supporting Information Table
S4).
In univariate analysis of PF tumors (n = 142), faster relapse was
seen for grade III (17 vs 22 months, P = 0.002), STR (18 vs 22 months,
P= 0.008), receipt of chemotherapy (18 vs 28months, P= 0.008), male
gender (18 vs 25months, P= 0.039), and lack of radiotherapy (17 vs 27
months, P= 0.001) (Supporting Information Figure S4). In multivariate
analysis, grade III (HR 1.586, P= 0.018) and STR (HR 0.617, P= 0.015)
remained associated with faster relapse (Supporting Information
Table S4).
with PF ependymomawho relapsed only once had an improvedOS comparedwith those who relapsedmore than once (P= 0.041). Analysis only
included patients with up to four relapses, with cases suffering higher numbers too low. (D) Pattern of relapsed supratentorial ependymoma. The
probability of further relapse remained at approximately 50%. (E) The interval between each recurrence did not significantly change for each
subsequent recurrence in the PF cohort (P= 0.430), although numbers for this analysis were small. Each survival curve represents the time for
each numbered recurrence to occur. (F) Patients with ST ependymomawho relapsed only once had no difference in OS comparedwith those who
relapsedmore than once (P= 0.397). Analysis only included patients with up to three relapses, with cases suffering higher numbers too low
F IGURE 2 (A) Proportion of cases who suffered different numbers of relapses bymolecular subgroup. (B) EPN_PFB and EPN_SPINE
subgroups displayed a lower relapse incidence than the EPN_PFA, EPN_RELA and EPN_YAP subgroups. For three EPN_RELA cases, the time to
relapse was not known, so was not included. (C) Patients with EPN_PFA tumors irradiated at first relapse had an improved EFS (P= 0.011)
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Age (continuous) 0.996 0.992-0.999 0.022 212 0.994 0.986-1.002 0.115 120
Gender (female vs
male)
0.796 0.571-1.110 0.179 209 – – – –
Grade (III vs II) 1.371 0.979-1.919 0.066 212 1.407 0.870-2.277 0.164 120
Resection (GTR vs
STR)




0.674 0.483-0.934 0.020 205 0.477 0.205-1.109 0.085 120
Chemotherapy
(yes vs no)
1.583 1.090-2.299 0.016 198 0.626 0.278-1.413 0.259 120
Chromosome 1q
(gain vs no gain)
1.902 1.230-2.943 0.004 132 3.042 1.819-5.087 <0.001 120
Supratentorial
tumors
Age (continuous) 0.998 0.993-1.004 0.537 70 – – – –
Gender (female vs
male)
0.978 0.517-1.849 0.944 70 – – – –
Grade (III vs II) 1.669 0.872-3.192 0.122 70 – – – –
Resection (GTR vs
STR)




0.562 0.295-1.071 0.080 69 – – – –
Chemotherapy
(yes vs no)
1.412 0.716-2.784 0.319 68 – – – –
Chromosome 1q
(gain vs no gain)
2.232 1.033-4.821 0.041 47 2.770 1.382-5.552 0.004 46
In ST cases (n=41), only grade III was associatedwith faster relapse
(22 vs 15months, P= 0.044) (Supporting Information Figure S5).
There was no difference in time to recurrence (P = 0.142) between
EPN_PFA and EPN_RELA tumors. Grade III EPN_PFA tumors relapsed
more quickly than grade II (P = 0.020). No other factors were signifi-
cant for themolecular subgroups.
3.5 Factors associatedwith survival of relapsed
patients
3.5.1 At primary diagnosis
No treatments at diagnosis were associated with OS at relapse in any
cohort (Supporting Information Table S5).
3.5.2 At relapse
In the combined cohort, patients with metastatic relapse had worse
median OS (20 vs 45 months, P = 0.022) and EFS (12 vs 20 months,
P = 0.040) (Figure 3A). Metastasis with or without local relapse had
equally poor outcomes (Supporting Information Figure S6A and B).
Irradiation, of any type, at first relapse was associated with early
improved median EFS (19 vs 8 months, P = 0.003) and OS (33 vs 20
months, P = 0.006) (Figure 3B).There was no difference between first
irradiation and reirradiation. Radiotherapy type (focal or CSI) was not
associated with outcome.
GTR at first relapse was associated with sustained improved EFS
(25% vs 0% 10-year survival, P = 0.013) (Figure 3C). Patients who
receivedneitherGTRnor radiotherapyhad thepoorest EFS (P=0.009)
(Supporting InformationFigure S6C). CombinedGTRand radiotherapy
were associated with delayed time to second relapse (P = 0.007) (Sup-
porting Information Figure S6D).
In univariate analysis of the PF cohort, patients with metastases
had worse median OS following relapse (20 vs 34 months, P = 0.034).
Radiotherapy of any type was associated with improved median EFS
(17 vs 4.5 months, P = 0.001) and OS (32 vs 9 months, P = 0.001),
a benefit also seen for EFS in the EPN_PFA cohort (19 vs 4 months,
P = 0.011). GTR at first recurrence was associated with improved EFS
but not OS (20 vs 10months, P= 0.048).
In multivariate analysis of PF tumors, improved EFS and OS were
associated with radiotherapy of any type (EFS: HR 0.483, 95% CI
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Age (continuous) 1.003 0.998-1.007 0.207 94 – – – –
Gender (female vs
male)
0.936 0.601-1.458 0.770 92 – – – –
Grade (III vs II) 1.612 1.020-2.545 0.041 94 1.791 1.067-3.006 0.027 86
Resection (GTR vs
STR)




1.158 0.747-1.797 0.512 92 – – – –
Chemotherapy
(yes vs no)
0.654 0.424-1.009 0.055 86 – – – –
Chromosome 1q
(gain vs no gain)
1.701 1.052-2.752 0.030 86 1.982 1.177-3.338 0.010 86
EPN_RELA
tumors
Age (continuous) 0.995 0.984-1.007 0.442 21 – – – –
Gender (female vs
male)
0.629 0.174-2.284 0.482 21 – – – –
Grade (III vs II) 1.043 0.273-3.985 0.951 21 – – – –
Resection (GTR vs
STR)




0.551 0.154-1.970 0.359 21 – – – –
Chemotherapy
(yes vs no)
0.851 0.217-3.330 0.816 20 – – – –
Chromosome 1q
(gain vs no gain)
4.307 1.178-15.757 0.027 20 – – – –
0.235-0.990, P= 0.047, OS: HR 0.439, 95%CI 0.208-0.927, P= 0.031)
but not GTR. Radiotherapy was also associated with improved EFS in
EPN_PFA (HR 0.180, 95%CI 0.583-0.557, P= 0.003).
There was no improved EFS, OS, or time to recurrence in ST or
EPN_RELA cohorts with any combination of surgery or radiotherapy.
4 DISCUSSION
Wepresent an analysis of relapsed pediatric ependymomahighlighting
its dismal prognosis. The large cohort, supported by extended follow-
up andmolecular data, has allowed amore comprehensive assessment
of outcomes than previously. The best predictor of relapse risk across
all subgroups was chromosome 1q gain. Although primary surgery and
irradiation reduced relapse risk variably in different intracranial loca-
tions, once a patient recurred these interventions gave, at best, short-
term benefits, confirming the need for better therapies.
Sixty-two percent of cases relapsed, with 57% five-year cumulative
incidence and no difference between intracranial locations. This was
higher than two recent studies,42,43 although all patients were irradi-
ated at primary diagnosis compared with 45% in our cohort. For irra-
diated patients, we found a similar relapse incidence to Ducassou42
(38% vs 31.3% for local relapses) but the incidence was still higher
than Merchant43 (16.2% for local relapses). A higher rate of GTR was
achieved in Merchant’s cohort and in the most recently published
study on ependymoma outcomes by Upadhyaya.12 However, a similar
rate to our study was seen by Ducassou.
Themajority of patientswho relapseddid sowithin twoyears.How-
ever, in agreement with previous studies,34,44 a number of patients
relapsed later, raising implications for follow-up duration. Very late
recurrences were heterogeneous with no clear demographic associ-
ations. Consistent with previous studies,26 patients presenting with
metastatic relapses had poor prognosis. We found metastatic relapse,
with or without local relapse, to have equally poor outcomes, in con-
trast to Messahel,2 where combined local and distant relapses had
poorer prognosis than distant only.
GTR and radiotherapy at primary diagnosis were associated with
reduced risk of, and increased time to, relapse with resection having
a greater impact on risk in ST tumors, and radiotherapy in PF tumors.
However, in agreement with previous research,44 neither treatment
prevented recurrence with approximately half of patients receiving
either intervention relapsing. GTR plus radiotherapy delayed relapse
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F IGURE 3 (A) Patients withmetastatic relapses had a significantly worse EFS (P= 0.040) andOS (P= 0.022), following first relapse.
(B) Irradiation at relapse improved EFS (P= 0.003) andOS (P= 0.006). (C) GTR at first relapse resulted in improved EFS (P= 0.013)
but did not reduce relapse risk or improveprognosis for relapsed cases,
comparedwith either treatment alone.
Although interventions at primary diagnosis reduced relapse risk
in univariate analysis, they did not confer improved OS for relapsed
patients. Treatment at relapse has lacked consensus but recent guide-
lines have recommended theuseof reirradiation and further surgery.20
We found both GTR and irradiation improved prognosis, in agree-
ment with previous studies.2,21-23,36,43 However, only short-term sur-
vival benefits were seen, which were limited to combined and PF
cohorts, raising questions about the best approach for patientswith ST
tumors.
Irradiation at relapse doubled time to further progression in com-
bined and PF cohorts but was associated with no difference in the
ST cohort. Furthermore, consistent with previous reports, we saw an
improved prognosis for patients receiving any radiotherapy at relapse,
whether or not they were irradiated at primary diagnosis.26 We saw
similar survival rates for reirradiated patients as Lobon et al.22 (30%
five-year OS). Higher rates for reirradiated patients were identified by
Tsang et al.23 (57% five-year OS) and Bouffet et al.21 (80% three-year
OS). However, both studies had shorter follow-up times (median; 1.8
and 3.7 vs 6.5 years).
The survival of PF patients irradiated at relapse was better than
those not irradiated, suggesting it confers short-term benefit but this
was not replicated in the ST group. We identified similar survival
rates for patients who were not irradiated at relapse to Zacharoulis
et al.26 (five-year OS 35% vs 26%). Survival rates in both our study and
Zacharoulis et al. were higher than Bouffet et al.21 (three-year OS 7%).
Patients who received chemotherapy at primary diagnosis had
higher relapse risk and shorter time to progression. This was likely due
to these being higher risk cases not receiving more beneficial treat-
ments, whichwas reflected in loss of significance inmultivariate analy-
sis in agreement with previous findings.26
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Tumor grade and patient age were associated with relapse
risk. There is disagreement as to the reliability of histological
grading.2,12,35,45 Our study suggests grade can correlate with outcome
in large retrospective cohorts from multiple centers. However, grade
did not remain a predictor of risk in the ST cohort, possibly reflecting
the smaller size of this group. The additional association of patient age
with relapse risk could have been influenced by variation in treatments
or molecular profiles, with EPN_PFA disproportionately affecting the
youngest children.31
Chromosome 1q gain has been associated with poorer
EFS.12,41,46,47 Our analysis demonstrated that it was also inde-
pendently associated with relapse risk across location and main
molecular subgroups. This builds on work by Upadhyaya who found
that 1q gain is associated with inferior outcomes in EPN_PFA.12 The
lack of associationwith outcome in the relapsed cohort suggests it was
not prognostic after relapse, in contrast to Tsang et al. who found the
marker to be prognostic in PF tumors with distant relapse.23
Relapse patterns within molecular subgroups have not previously
been investigated in detail.31,48 We found relapse risk was higher for
EPN_PFA compared with EPN_RELA cases, which agrees with studies
where EPN_PFA cases displayed a poorer EFS.31 However, EPN_RELA
cases, on average, suffered more relapses. Despite these differences,
relapsed patients from both subtypes had poor prognosis, suggesting
that although subtypes are biologically and clinically distinct, relapse is
important for both.
Despite small numbers, we identified relapsed cases in EPN_PFB
and EPN_YAP subgroups. The majority of these cases demonstrated
long-term survival, consistent with previously reported favorable
prognosis.31,48
Interestingly, if EPN_PFA and EPN_RELA subgroups were consid-
ered independently, surgery and radiotherapy were not associated
with relapse risk. For relapsed EPN_PFA cases, radiotherapy was asso-
ciatedwithbetterEFS, although radiotherapyandGTRhavepreviously
been associated with improved EFS In EPN_PFA, the association was
not seen across all cohorts analyzed.31,48 EPN_RELA cases have only
been investigated previously by Pajtler et al.31 who found irradiation,
but not GTR, was associated with improved EFS. In light of these con-
tradictory data, further work is needed to fully understand the impact
of therapy on themolecular subgroups at diagnosis and recurrence.
Extended follow-up of our cohort provided more detail on long-
term outcomes of relapsed ependymoma than previous work.2,34,37,50
Whilst treatment approaches have changed little over time, improve-
ments in resources and support strategies may mean that this study
provides an overly pessimistic outlook. In particular, reported GTR
rates are higher in more recent studies.12 However, we have demon-
strated that childrenwith GTR still do relapse, and it is undeniable that
outcomes for children with relapsed ependymoma remain remarkably
poor.
Inclusion of data from multiple centers provides a wider snapshot
of ependymoma. However, this has the disadvantage of lack of unifor-
mity in treatment approaches, particularly at recurrence. An additional
challenge resulting from the retrospective nature of the data was that
numberswith complete data for analysis of radiotherapy type at recur-
rence(focal vs CSI) were low. Whether reirradiation should be focal
or craniospinal remains an important question that this retrospective
study could not answer. A prospective, randomized study is needed to
address this question.
A further limitation is the lack of central imaging review at recur-
rence and this should be performed in the future to standardize diag-
nosis. Finally, the inclusion of large numbers of young children made
detailed analysis of non-EPN_PFA entities challenging. Further stud-
ies into relapse outcomes for other molecular subgroups are urgently
needed.
In conclusion, recurrent pediatric ependymoma is highly aggressive
with extremely poor outcomes. The data suggest relapsed cases form a
subset for whom current therapies are inadequate. Relapsed patients
with EPN_PFA and EPN_RELA tumors had an equally poor prognosis
suggesting relapse is important across major pediatric subtypes with
gainof1qbeingauniversal predictorof pooroutcome.Adeeperunder-
standing of recurrence biology, inmolecularly stratified cohorts, is also
needed to identify drivers of relapse.
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